Ascletis announces asc47, a muscle-preserving weight loss drug candidate for treatment of obesity, demonstrated greater efficacy with tirzepatide than semaglutide in a preclinical model

-         the combination of asc47 low dose with tirzepatide in diet-induced obese (dio) mice resulted in an 87% greater reduction in body weight compared to tirzepatide monotherapy.  -          asc47 low dose in combination with tirzepatide demonstrated statistically significantly greater increase in efficacy than asc47 low dose in combination with semaglutide, 87% vs 55%, respectively, in the dio mouse model.
ASC Ratings Summary
ASC Quant Ranking